Programmed cell death is a genetically regulated process of cell suicide that is central to the development, homeostasis and integrity of multicellular organisms. The dysregulation of mechanisms controlling cell suicide plays a role in the pathogenesis of a wide range of diseases. Apoptosis is the earliest and most recognized programmed cell death that is regulated by specific signals. Since then, more and more programmed cell death has been discovered and defined, such as autophagy, pyroptosis, ferroptosis and NETosis, etc.
Accumulating evidence demonstrated that traditional medicines could regulate program cell death as mechanisms of therapeutic effects, not only for killing tumor cells but also promoting the proliferation, migration and differentiation of stem cells. In addition, amelioration of chronic inflammatory diseases through various pathways of programmed cell death is a novel strategy. The research topic will promote pharmacological and clinical research in this field focusing on medicinal plants and their metabolites
Traditional and local medicines are and have been used widely for chronic inflammatory diseases. Based on local and traditional uses in inflammatory diseases could be a basis for investigating programmed cell death in vitro or in vivo.
The active metabolites of traditional medicines involved in regulating programmed cell death, if they have a specific effect merit a more detailed mechanistic – pharmacological approach.
This goal of this research topic is to understand traditional medicines or their metabolites against inflammation in relation to programmed cell death
Effect of traditional medicine and metabolites against the following inflammatory diseases in relation to program cell death regulation using animal and cell models are of particular interest for this research topic:
• Endocrine disorders such as diabetes and metabolic syndrome
• Chronic liver diseases such as steatosis and hepatocholangitis
• Chronic kidney diseases such as glomerulonephritis, kidney and urinary tract inflammation
• Chronic lung diseases such as chronic obstructive pulmonary disease and chronic bronchitis,
• Cardiovascular diseases such as rheumatic heart disease, deep vein thrombosis and pulmonary embolism.
• Neurodegenerative diseases such as Alzheimer’s disease. Parkinson’deseases, etc.
• Tumor chemotherapy resistance and anticancer therapy.
• Crosstalk between different programmed cell death processes in chronic inflammatory diseases.
• Crosstalk between programmed cell death processed in stem cell therapy.
In general such experimental studies must be based on local and traditional uses of the species investigated and this must be documented using primary literature.. All manuscripts must comply with our guidelines - the four pillars of best practice in ethnopharmacology (see www.frontiersin.org/files/pdf/4_pillars_FULL_TEXT.pdf) Specifically, please note the need to phytochemically characterise the preparations used in detail (see https://doi.org/10.3389/fphar.2022.953205). In silico studies of plants/fungi and their extracts are outside of the journals scope.
Programmed cell death is a genetically regulated process of cell suicide that is central to the development, homeostasis and integrity of multicellular organisms. The dysregulation of mechanisms controlling cell suicide plays a role in the pathogenesis of a wide range of diseases. Apoptosis is the earliest and most recognized programmed cell death that is regulated by specific signals. Since then, more and more programmed cell death has been discovered and defined, such as autophagy, pyroptosis, ferroptosis and NETosis, etc.
Accumulating evidence demonstrated that traditional medicines could regulate program cell death as mechanisms of therapeutic effects, not only for killing tumor cells but also promoting the proliferation, migration and differentiation of stem cells. In addition, amelioration of chronic inflammatory diseases through various pathways of programmed cell death is a novel strategy. The research topic will promote pharmacological and clinical research in this field focusing on medicinal plants and their metabolites
Traditional and local medicines are and have been used widely for chronic inflammatory diseases. Based on local and traditional uses in inflammatory diseases could be a basis for investigating programmed cell death in vitro or in vivo.
The active metabolites of traditional medicines involved in regulating programmed cell death, if they have a specific effect merit a more detailed mechanistic – pharmacological approach.
This goal of this research topic is to understand traditional medicines or their metabolites against inflammation in relation to programmed cell death
Effect of traditional medicine and metabolites against the following inflammatory diseases in relation to program cell death regulation using animal and cell models are of particular interest for this research topic:
• Endocrine disorders such as diabetes and metabolic syndrome
• Chronic liver diseases such as steatosis and hepatocholangitis
• Chronic kidney diseases such as glomerulonephritis, kidney and urinary tract inflammation
• Chronic lung diseases such as chronic obstructive pulmonary disease and chronic bronchitis,
• Cardiovascular diseases such as rheumatic heart disease, deep vein thrombosis and pulmonary embolism.
• Neurodegenerative diseases such as Alzheimer’s disease. Parkinson’deseases, etc.
• Tumor chemotherapy resistance and anticancer therapy.
• Crosstalk between different programmed cell death processes in chronic inflammatory diseases.
• Crosstalk between programmed cell death processed in stem cell therapy.
In general such experimental studies must be based on local and traditional uses of the species investigated and this must be documented using primary literature.. All manuscripts must comply with our guidelines - the four pillars of best practice in ethnopharmacology (see www.frontiersin.org/files/pdf/4_pillars_FULL_TEXT.pdf) Specifically, please note the need to phytochemically characterise the preparations used in detail (see https://doi.org/10.3389/fphar.2022.953205). In silico studies of plants/fungi and their extracts are outside of the journals scope.